Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70.
OBJECTIVE
Alveolar fluid clearance is impaired by inducible nitric oxide synthase (iNOS)/nitric oxide (NO)-dependent mechanisms in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). The activation of the stress protein response (SPR) in alveolar macrophages on iNOS-dependent NO production in response to interferon gamma (IFNgamma), a major cytokine present in the airspace of patients with ALI, was investigated.


METHODS
The SPR was activated in murine and primary human alveolar macrophages prior to analysis of signal transducer and activator of transcription factor 1 (STAT1) activation, iNOS mRNA and protein synthesis, and NO production.


RESULTS
SPR activation resulted in inhibition of IFNgamma-mediated NO production (p=0.001) with >95% detergent insolubilisation of the STAT1 protein. Its subsequent proteasomal degradation was partially reversed with pretreatment of cells with the chemical chaperone glycerol. This early effect of the SPR was caused by the complete disruption of heat shock protein 90 (Hsp90)-STAT1 binding, as shown by immunoprecipitation. Recovery of STAT1 activation and recovery of iNOS synthesis occurred within 12 h after SPR activation (p=0.02). NO production (as compared with non-SPR controls) did not occur until 48 h later (p=0.02). SPR-induced Hsp70 (Hsp70i) expression caused a late inhibition of NO production (p=0.02). Inhibiting >50% Hsp70i expression recovered NO production to control levels whereas overexpressing Hsp70i in the absence of the SPR inhibited NO production (p=0.02).


CONCLUSIONS
Early inhibition of STAT1 following its dissociation from Hsp90, and later inhibition of iNOS activity by Hsp70i, represent novel mechanisms by which SPR activation modulates the IFNgamma signalling in alveolar macrophages. These results highlight a potential clinical application for Hsp90 inhibitors in modulating NO signalling during the early phase of acute lung injury.
Howard
Marybeth
M
Laboratory of Surgical Research, Department of Anesthesia, University of California, San Francisco, CA 94110, USA. howardm@anesthesia.ucsf.edu
Roux
Jérémie
J
Lee
Hyon
H
Miyazawa
Byron
B
Lee
Jae-Woo
JW
Gartland
Brandi
B
Howard
Amanda J
AJ
Matthay
Michael A
MA
Carles
Michel
M
Pittet
Jean-François
JF
D000818:Animals; D002460:Cell Line; D005786:Gene Expression Regulation / Q000187:drug effects; D018840:HSP70 Heat-Shock Proteins / Q000502:physiology*; D018841:HSP90 Heat-Shock Proteins / Q000502:physiology*; D006358:Hot Temperature; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics; D050794:STAT1 Transcription Factor / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D013312:Stress, Physiological / Q000187:drug effects / Q000502:physiology
D018840:HSP70 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins; D012333:RNA, Messenger; D050794:STAT1 Transcription Factor; D009569:Nitric Oxide; D007371:Interferon-gamma; D052247:Nitric Oxide Synthase Type II
N Engl J Med. 2000 May 4;342(18):1334-49
10793167
Am J Respir Cell Mol Biol. 2000 Jun;22(6):708-13
10837368
Am J Physiol. 1998 Mar;274(3):L369-77
9530172
J Appl Physiol (1985). 2004 Aug;97(2):564-9
15090481
J Biol Chem. 1991 Jul 25;266(21):13941-6
1906889
Trends Mol Med. 2004 Jun;10(6):283-90
15177193
Proteomics. 2004 Nov;4(11):3335-42
15378740
Science. 2000 Jun 30;288(5475):2357-60
10875919
Am J Physiol Lung Cell Mol Physiol. 2006 Sep;291(3):L354-61
16679378
FASEB J. 2005 Feb;19(2):287-9
15550551
Exp Biol Med (Maywood). 2003 Feb;228(2):111-33
12563018
J Neurosci Res. 2002 Feb 15;67(4):461-70
11835313
J Clin Invest. 1998 Jul 1;102(1):184-93
9649572
Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1439-45
10775120
Am J Respir Crit Care Med. 2001 May;163(6):1376-83
11371404
Physiol Rev. 1992 Oct;72(4):1063-81
1438579
J Immunol. 2005 Jan 1;174(1):384-94
15611262
J Clin Invest. 2002 Sep;110(6):801-6
12235111
J Biol Chem. 2005 May 13;280(19):18579-89
15755725
J Biol Chem. 2002 Nov 22;277(47):45662-9
12235142
Br J Surg. 1998 Jul;85(7):943-6
9692569
J Physiol. 2002 Jan 15;538(Pt 2):583-97
11790821
Biochem J. 2000 Oct 1;351(Pt 1):257-64
10998369
J Biol Chem. 2002 Nov 8;277(45):43041-9
12194970
J Biol Chem. 1997 Nov 7;272(45):28563-7
9353320
Am J Respir Crit Care Med. 2001 Jan;163(1):166-72
11208643
J Biol Chem. 2006 Jan 27;281(4):1876-84
16280321
Immunology. 2003 Apr;108(4):513-22
12667213
Annu Rev Biochem. 1995;64:621-51
7574495
Curr Cancer Drug Targets. 2003 Oct;3(5):377-83
14529389
J Mol Med (Berl). 2004 Aug;82(8):488-99
15168026
J Immunol. 2001 May 15;166(10):6301-10
11342654
J Biol Chem. 2003 Sep 19;278(38):36953-8
12855682
Cancer Res. 2007 Mar 15;67(6):2865-71
17363610
J Heart Lung Transplant. 1998 Dec;17(12):1238-46
9883766